TMTPOST — Shanghai Yingjiexin Medical Technology has completed a Series B financing of 200 million yuan. The round was led by a fund under CICC Capital, with participation from Zhuhai Science and Technology Industry Group, Keystone Capital, Qiming Venture Partners, Houxin Health Investment and Yingyue Fund. Existing shareholder GSR Ventures continued its investment, and Haoyue Capital served as exclusive financial adviser. Proceeds will expand global production and delivery capacity, accelerate research and commercialization of next-generation self-administration devices, and support overseas product registration, market expansion and customer service systems. The company focuses on high-precision drug delivery devices for biologics such as GLP-1 agonists and insulin.